# Vaxxas

> Vaxxas is a Brisbane-based clinical-stage biotechnology company developing a high-density microarray patch (HD-MAP) that delivers dry-coated vaccines into the skin. It partners with vaccine developers, governments and global-health funders on formulation, clinical development and manufacturing; its patch vaccines remain investigational.

- **Founded:** 2011
- **Headquarters:** Brisbane, Australia
- **Founders:** Mark Kendall (Founder and inventor; former Chief Technology Officer)
- **Products:** High-Density Microarray Patch (HD-MAP), Vaccine platform licensing and co-development, RSV vaccine development program
- **Notable:** Company reports six Phase I trials involving more than 750 participants., 2020 peer-reviewed influenza trial found antibody titres with 2.5 micrograms of patch-delivered antigen were not significantly different from 15 micrograms injected intramuscularly., Opened a 5,500-square-metre Brisbane biomedical facility in June 2023.

## Products & services

- **High-Density Microarray Patch (HD-MAP)** — Investigational injection-moulded polymer patch with thousands of approximately 0.25 mm microprojections, dry-coated with vaccine and integrated into a single-use applicator.
- **Vaccine platform licensing and co-development** — Formulation, coating, device, manufacturing and development capabilities offered to vaccine partners.
- **RSV vaccine development program** — Vaxxas has licensed a next-generation RSV vaccine candidate from the US NIH for development with its delivery platform.

## Achievements

- Company reports six Phase I trials involving more than 750 participants.
- 2020 peer-reviewed influenza trial found antibody titres with 2.5 micrograms of patch-delivered antigen were not significantly different from 15 micrograms injected intramuscularly.
- Opened a 5,500-square-metre Brisbane biomedical facility in June 2023.
- TGA granted a manufacturing licence on 11 December 2025.
- Consortium selected for phase one of EU HaDEA influenza initiative in February 2026.

## Latest updates

- **2026-09** — Launched a public-attitudes and acceptability study in Germany, France and Italy under the HaDEA-funded influenza consortium.
- **2026-02** — Vaxxas, SK bioscience and IDT Biologika selected for phase one of EU influenza development program; up to A$250 million is available across the program’s three competitive phases, not an award solely to Vaxxas.
- **2026-01** — Appointed former Merck Global Vaccines president David Peacock as CEO.
- **2025-12** — Announced TGA manufacturing licence; regulator lists grant date as 11 December.
- **2025-08** — Announced A$49.22 million Series D equity and A$40 million debt facility to support production scale-up and clinical development.

## Links

- Website: https://www.vaxxas.com/
- LinkedIn: https://www.linkedin.com/company/vaxxas/

---

Profile page: https://yespress.io/vaxxas
Published by YesPress — https://yespress.io
Last updated: 2026-10-15